Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective
Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality
and major disability in the Indian subcontinent. It is most neglected tropical disease …
and major disability in the Indian subcontinent. It is most neglected tropical disease …
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis
S Palić, JH Beijnen, TPC Dorlo - International Journal of Antimicrobial …, 2022 - Elsevier
Miltefosine is an alkylphosphocholine agent with a broad spectrum of antiparasitic
properties. For over two decades, miltefosine has remained the only oral drug licensed and …
properties. For over two decades, miltefosine has remained the only oral drug licensed and …
Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical …
It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …
variation among patients. They are not intended to supplant physician judgment with respect …
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance
Abstract Background. Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is
currently the first-line therapy in the VL elimination program of the Indian subcontinent …
currently the first-line therapy in the VL elimination program of the Indian subcontinent …
Vaccines to prevent leishmaniasis
Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …
affecting people in tropical and subtropical regions of the world. Epidemiological and …
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
Background Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are
increasingly being reported. However, there has been no laboratory confirmed reports of …
increasingly being reported. However, there has been no laboratory confirmed reports of …
Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
EE Zijlstra, F Alves, S Rijal, B Arana… - PLoS neglected tropical …, 2017 - journals.plos.org
Background The South-East Asia Region Kala-azar Elimination Programme (KAEP) is
expected to enter the consolidation phase in 2017, which focuses on case detection, vector …
expected to enter the consolidation phase in 2017, which focuses on case detection, vector …
Tackling drug resistance and other causes of treatment failure in leishmaniasis
Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …
The disease is transmitted by female sand flies and, depending on the infecting parasite …
Drug resistance in leishmaniasis: Newer developments
S Mohapatra - Tropical parasitology, 2014 - journals.lww.com
Leishmaniasis is a vector borne protozoan disease and it remains a major public health
problem world-wide. Lack of an effective vaccine and vector control program makes the …
problem world-wide. Lack of an effective vaccine and vector control program makes the …
Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure
TPC Dorlo, S Rijal, B Ostyn, PJ de Vries… - The Journal of …, 2014 - academic.oup.com
Background. Recent reports indicated high miltefosine treatment failure rates for visceral
leishmaniasis (VL) on the Indian subcontinent. To further explore the pharmacological …
leishmaniasis (VL) on the Indian subcontinent. To further explore the pharmacological …